Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR and PD-1 Knockout T Cells for B-cell Leukemia and Lymphoma
NCT03298828Phase 1Unknown
- Sponsor
- Army Medical University
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label trial of CD19 CAR and PD-1 knock out engineered T-cells in acute lymphoblastic leukemia (ALL) and Burkitt lymphoma (BL), sponsored by Army Medical University. Status: unknown.
02
Drugs
CD19 CAR and PD-1 knock out engineered T-cells
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT03298828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298828.